Personalized Medicine Meets Thyroid Cancer: Drug Targeting BRAF Mutation Helps Patients
Perelman School of Medicine at the University of PennsylvaniaResearchers from Penn Medicine and other institutions found that treating metastatic thyroid cancer patients harboring a BRAF mutation with the targeted therapy vemurafenib —originally approved for melanoma patients with the mutation—showed promising anti-tumor activity in a third of patients. The results were published in this week’s Lancet Oncology.